| Project/Area Number |
15H04685
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
永森 收志 大阪大学, 医学系研究科, 准教授 (90467572)
大垣 隆一 大阪大学, 医学系研究科, 助教 (20467525)
奥田 傑 大阪大学, 医学系研究科, 助教 (50511846)
中込 咲綾 大阪大学, 医学(系)研究科(研究院), 特任助教(常勤) (60423894)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2017: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2016: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2015: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Keywords | トランスポーター / 受容体 / シグナル伝達系 / 細胞代謝制御 / 抗腫瘍薬 / がん / アミノ酸トランスポーター / リン酸化プロテオミクス / 腫瘍血管新生 / チャネル / 輸送系 / シグナル情報伝達系 / 輸送体介在シグナル / 代謝制御・細胞機能制御 |
|---|
| Outline of Final Research Achievements |
Amino acid transporter LAT1 (L-type amino acid transporter 1) is highly upregulated in various types of cancer. LAT1 is known to supply cancer cells with most of the essential amino acids, thereby supporting the rapid cell growth and proliferation. By using newly developed LAT1-selective inhibitor, we tried to understand the functions of amino acids as signaling molecules, and to reveal the cellular metabolisms and other cellular functions regulated by amino acids transported by LAT1, especially leucine. Phosphoproteomics analysis revealed amino acid signaling in the downstream of LAT1. We also demonstrated relationships between LAT1 with tumor angiogenesis and metastasis. This research revealed novel functional aspects of the amino acid transporter and amino acid signaling. The results obtained also contributed to the comprehensive understanding of the mechanisms of action of LAT1 inhibitors as a novel class of anti-cancer agents.
|
